TCGA-OR-A5JE-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.479
- CHOLESTEROL_HOMEOSTASIS+0.445
- OXIDATIVE_PHOSPHORYLATION+0.438
- E2F_TARGETS+0.425
- DNA_REPAIR+0.407
- PANCREAS_BETA_CELLS+0.399
- MTORC1_SIGNALING+0.380
- FATTY_ACID_METABOLISM+0.369
- INTERFERON_ALPHA_RESPONSE+0.350
- MYC_TARGETS_V2+0.338
Top 10 suppressed
- PROTEIN_SECRETION-0.322
- UV_RESPONSE_DN-0.293
- TGF_BETA_SIGNALING-0.181
- TNFA_SIGNALING_VIA_NFKB-0.149
- WNT_BETA_CATENIN_SIGNALING-0.140
- HYPOXIA-0.119
- MITOTIC_SPINDLE-0.112
- HEDGEHOG_SIGNALING-0.110
- KRAS_SIGNALING_UP-0.110
- HEME_METABOLISM-0.103
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OR-A5K2-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.890 |
| 2 | 7a458b19-1b7c-422c-b900-cd77e5009421 | — | — | 0.808 |
| 3 | SRR8518397 | — | E | 0.795 |
| 4 | SRR11296765 | — | — | 0.793 |
| 5 | MNG358 | — | — | 0.792 |
| 6 | 1a68a242-045b-4566-afd7-192df87b02d3 | — | — | 0.791 |
| 7 | 94a92a4a-6c40-40c4-913d-0cdba8cb5892 | — | — | 0.789 |
| 8 | MNG713 | — | — | 0.784 |
| 9 | TCGA-E2-A9RU-01A-11R-A41B-07 | — | B | 0.784 |
| 10 | SRR25043611 | — | — | 0.779 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.479 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.445 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.438 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.425 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.407 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.399 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.380 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.369 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.338 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.312 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.297 | Inavolisib | — uncovered |
| PEROXISOME | 0.283 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.268 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.208 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.206 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.142 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.135 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.131 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.115 | Idelalisib | — uncovered |